← Back to Patent Explorer
US3931399A Expired / Lapsed US ⏱️ 0.0 years remaining

Process for isolating a fibrin-stabilizing factor

Assignee: Siemens Healthcare Diagnostics GmbH Germany
•
Filing: 1973-12-21
•
Granted: 1976-01-06
•
Expires: 1993-12-21
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A process for isolating a fibrin-stabilizing factor, factor XIII, by extracting human placentae with sodium chloride solution; adding diamino-ethoxy-acridine lactate (DEAL); recovering the resultant precipitate and dissolving it in dilute alkali metal chloride solution containing a complexing agent; adding a quaternary ammonium base to the solution to precipitate inactive materials; reprecipitating the active principal from solution with DEAL; again dissolving the precipitate in dilute alkali metal chloride solution containing a complexing agent; reprecipitating the active principal by adding solid ammonium sulfate; forming a paste between the precipitate and a dilute solution of a complexing agent; dialyzing the paste; gel filtering the dialyzed product; precipitating the active principal from the active fractions with ammonium sulfate; dissolving the precipitate in a neutral tris-(hydroxymethyl)-aminomethane hydrochoric acid buffer containing a complexing agent; dialyzing the solution; and precipitating the factor XIII from the remaining solution in the form of euglobulin.

Inventors

  • 👤 Hans Bohn
  • 👤 Fritz Emmerich

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 23:40
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/10; C12N9/1025; C12N9/104; C12N9/1044; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/85; Y10S530/851

Claims Analysis

Total Claims: 2
Claim 1
Independent Claim 485 words
A process for isolating a fibrin-stabilizing factor which comprises: a. extracting human placentae at a temperature from 0°C. to 20°C. with a dilute aqueous sodium chloride solution and removing solid contaminants from the extract; b. adding a dilute aqueous solution of diaminoethoxy-acridine lactate to said extract at a temperature from 5°C. to 20°C. and at a pH between 5.0 and 7.5 in an amount furnishing 6 to 10 grams of said lactate per 100 grams of protein content in said extract to form a first precipitate, and isolating said first precipitate; c. dissolving said precipitate at a temperature from 5°C. to 20°C. in a dilute solution of alkali metal chloride at a pH between 7.0 and 8.0, said solution containing about 5 percent, by weight of said alkali metal chloride, of a complexing agent selected from the group consisting of ethylene diamine tetraacetic acid and nitrilo-triacetic acid, and removing any insoluble substances from the solution; d. adding a quaternary ammonium base to the solution in an amount from 0.04 to 0.08 percent, by weight of the solution, at a temperature from 5°C. to 20°C. to form a second precipitate, and removing and discarding this second precipitate; e. adding a dilute aqueous solution of diaminoethoxy-acridine lactate to the solution at a temperature from 5°C. to 20°C. to form a third precipitate, and isolating said third precipitate; f. dissolving said third precipitate in a dilute solution of an alkali metal chloride at a temperature from 5°C. to 20°C. and at a pH between 7.0 and 8.0, said solution containing about 5 percent, by weight of said alkali metal chloride, of ethylene diamine tetraacetic acid or nitrilo-triacetic acid and removing any insoluble substances from the solution; g. adding 20 to 30 percent of solid ammonium sulfate to the solution to form a fourth precipitate, and isolating said fourth precipitate; h. forming a paste from said fourth precipitate and a dilute solution of ethylene diamine tetraacetic acid or nitrilo-triacetic acid and dialyzing said paste against tris(hydroxymethyl)-aminoethane/hydrochloric acid buffer containing ethylene diamine tetraacetic acid or nitrilo-triacetic acid and sodium azide, whereby the paste is solubilized; i. adjusting the pH of the dialyzed solution to 6.0 to form a fifth precipitate which is separated and discarded, and readjusting the pH to 7.0; j. gel filtering the solution on cross-linked dextran, eluting with tris(hydroxymethyl)-aminomethane/hydrochloric acid buffer containing ethylene diamine tetraacetic acid or nitrilo-triacetic acid and sodium azide, and collecting and combining active fractions having an activity of more than 2 units of fibrin-stabilizing factor; k. adding sufficient solid ammonium sulfate to the collected active fractions to form a sixth precipitate containing the fibrin-stabilizing factor, and isolating said sixth precipitate; l. dissolving said sixth precipitate in a neutral tris(hydroxymethyl)-aminomethane/ethylene diamine tetraacetic acid buffer; m. dialyzing the solution against neutral tris(hydroxymethyl)-aminomethane/ethylene diamine tetraacetic acid buffer; n. adjusting the pH of the dialyzed solution to 5.0 to precipitate the fibrin-stabilizing factor and isolating the precipitate.
Claim 2
Dependent Claim 485 words
A process for isolating a fibrin-stabilizing factor which comprises: a. extracting human placentae at a temperature from 0°C. to 20°C. with a dilute aqueous sodium chloride solution and removing solid contaminants from the extract; b. adding a dilute aqueous solution of diaminoethoxy-acridine lactate to said extract at a temperature from 5°C. to 20°C. and at a pH between 5.0 and 7.5 in an amount furnishing 6 to 10 grams of said lactate per 100 grams of protein content in said extract to form a first precipitate, and isolating said first precipitate; c. dissolving said precipitate at a temperature from 5°C. to 20°C. in a dilute solution of alkali metal chloride at a pH between 7.0 and 8.0, said solution containing about 5 percent, by weight of said alkali metal chloride, of a complexing agent selected from the group consisting of ethylene diamine tetraacetic acid and nitrilo-triacetic acid, and removing any insoluble substances from the solution; d. adding a quaternary ammonium base to the solution in an amount from 0.04 to 0.08 percent, by weight of the solution, at a temperature from 5°C. to 20°C. to form a second precipitate, and removing and discarding this second precipitate; e. adding a dilute aqueous solution of diaminoethoxy-acridine lactate to the solution at a temperature from 5°C. to 20°C. to form a third precipitate, and isolating said third precipitate; f. dissolving said third precipitate in a dilute solution of an alkali metal chloride at a temperature from 5°C. to 20°C. and at a pH between 7.0 and 8.0, said solution containing about 5 percent, by weight of said alkali metal chloride, of ethylene diamine tetraacetic acid or nitrilo-triacetic acid and removing any insoluble substances from the solution; g. adding 20 to 30 percent of solid ammonium sulfate to the solution to form a fourth precipitate, and isolating said fourth precipitate; h. forming a paste from said fourth precipitate and a dilute solution of ethylene diamine tetraacetic acid or nitrilo-triacetic acid and dialyzing said paste against tris(hydroxymethyl)-aminoethane/hydrochloric acid buffer containing ethylene diamine tetraacetic acid or nitrilo-triacetic acid and sodium azide, whereby the paste is solubilized; i. adjusting the pH of the dialyzed solution to 6.0 to form a fifth precipitate which is separated and discarded, and readjusting the pH to 7.0; j. gel filtering the solution on cross-linked dextran, eluting with tris(hydroxymethyl)-aminomethane/hydrochloric acid buffer containing ethylene diamine tetraacetic acid or nitrilo-triacetic acid and sodium azide, and collecting and combining active fractions having an activity of more than 2 units of fibrin-stabilizing factor; k. adding sufficient solid ammonium sulfate to the collected active fractions to form a sixth precipitate containing the fibrin-stabilizing factor, and isolating said sixth precipitate; l. dissolving said sixth precipitate in a neutral tris(hydroxymethyl)-aminomethane/ethylene diamine tetraacetic acid buffer; m. dialyzing the solution against neutral tris(hydroxymethyl)-aminomethane/ethylene diamine tetraacetic acid buffer; n. adjusting the pH of the dialyzed solution to 5.0 to precipitate the fibrin-stabilizing factor and isolating the precipitate.

References Cited (Backward Citations)

US3497492A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1979-01-05 1979-07-07 1980-01-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1983-01-05 1983-07-07 1984-01-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1987-01-05 1987-07-07 1988-01-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag